Navigation Links
Celladon Corporation Completes $43 Million Financing to Advance MYDICAR® for the Treatment of Heart Failure
Date:2/15/2012

LA JOLLA, Calif., Feb. 15, 2012 /PRNewswire/ -- Celladon Corporation, a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, announced today that it has completed a $43 million equity financing to advance its lead investigational product candidate MYDICAR® for the treatment of heart failure. The financing was led by new investor Pfizer Venture Investments and also included new investors Lundbeckfond Ventures, Novartis Venture Funds, H&Q Healthcare/Life Sciences Investors, and GBS Venture Partners. All previous investors participated in this round including Enterprise Partners Venture Capital, Johnson & Johnson Development Corporation, and Venrock Associates.

In conjunction with this financing, Celladon has added a new slate of directors to its board including Barbara Dalton, Ph.D., of Pfizer Venture Investments (Chair), Johan Kordel, Ph.D., Assoc. Prof., of Lundbeckfond Ventures, Lauren Silverman, Ph.D., of Novartis Venture Funds, Daniel Omstead, Ph.D., of Hambrecht & Quist Capital Management, and Josh Funder, D.Phil., of GBS Venture Partners.  In addition, Andrew Senyei, M.D., of Enterprise Partners Venture Capital will continue to serve as a director.

"We are pleased to have attracted such a top tier syndicate to support advancement of MYDICAR for the benefit of advanced heart failure patients," said Krisztina Zsebo Ph.D., President and CEO of Celladon Corporation. Dr. Zsebo continued, "The positive results of the phase 2 CUPID Trial demonstrated the potential of MYDICAR to become an important treatment for patients with chronic, advanced heart failure."

Celladon Corporation plans to advance the clinical development of MYDICAR in 2012. MYDICAR was recently granted Fast Track Status by the Food and Drug Administration in December, 2011.

"MYDICAR has demonstrated clinical benefit in human clinical trials and we believe that it has the poten
'/>"/>

SOURCE Celladon Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Celladon Corporation Receives FDA Fast Track Designation for Its Investigational Agent MYDICAR® for the Treatment of Heart Failure
2. Celladon Corporation Announces MYDICAR® Enzyme Replacement Therapy for Advanced Heart Failure Provides Sustained Reduction in Clinical Events in Patients for 18 Months Compared with Placebo
3. Celladon Provides MYDICAR(R) Program Update of First-In-Human Trial for Advanced Heart Failure at American Society of Gene Therapy Annual Meeting
4. Celladon Corporation Announces Presentation of First-in-Human Gene Transfer to Treat Heart Failure at the 12th Annual Meeting of the American Society of Gene Therapy
5. Celladon Announces Presentation of Clinical Data From First-in-Human MYDICAR(R) Trial for Advanced Heart Failure at American Heart Association Scientific Sessions
6. Unilife Corporation Announces Financial Results for Fiscal Year 2012 Second Quarter
7. Volcano Corporation Schedules Fourth Quarter Conference Call, Webcast
8. Luminex Corporation Reports Fourth Quarter and Full Year 2011 Results
9. Unilife Corporation to Announce Financial Results for Fiscal 2012 Second Quarter on Thursday, February 9, 2012
10. Vystar® Corporation Receives its Third US Patent and First Chinese Patent for Vytex® Natural Rubber Latex
11. Kensey Nash Corporation Announces Its Second Quarter Fiscal Year 2012 Earnings Release Date and Teleconference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... Calif. , June 30, 2015  Ardelyx, Inc. ... on cardio-renal, gastrointestinal and metabolic diseases, today announced that ... July 14, 2015, from 8:00 a.m.- 1:00 pm EDT ... The Ardelyx senior management team will present ... lead compound, tenapanor, which has completed Phase 2b clinical ...
(Date:6/30/2015)... , BERKELEY, Kalifornien, und KOPENHAGEN, Dänemark, ... Biologics, Inc. , ein Weltmarktführer der klinischen ... anderen therapeutischen Proteinen, gab heute bekannt, dass ... der Produktionskapazität den Ausbau der nordamerikanischen Produktionsanlage ... mit der Ergänzung  einer Einweg-Anlage Bioreactor 6Pack™ ...
(Date:6/30/2015)... , June 24, 2015 Research ... of the "Global Endoscopy Devices Market 2015-2019" ... global endoscopy devices market to grow at a ... The global endoscopy devices market can be segmented ... accessories, and services. The market can be further ...
Breaking Medicine Technology:Ardelyx to Host Inaugural R&D Investor Day in New York City on July 14, 2015 2CMC Biologics baut GMP-Produktionskapazität in den USA aus 2CMC Biologics baut GMP-Produktionskapazität in den USA aus 3Global Endoscopy Devices Market 2015-2019 - Key Players are Boston Scientific, Johnson and Johnson, Medtronic, Karl Storz & Olympus 2Global Endoscopy Devices Market 2015-2019 - Key Players are Boston Scientific, Johnson and Johnson, Medtronic, Karl Storz & Olympus 3
... Cynosure, Inc. (Nasdaq: CYNO ), a ... and non-invasive aesthetic applications, today announced that two of ... reduction have received key international regulatory clearances. ... authorizing the sale in Canada of the company,s SmoothShapes® ...
... HealthWarehouse.com, Inc. (OTC: HEWA), a leading ... will be presenting at the following upcoming event ... Stock ConferenceDate: March 16, 2011Time: 12:30pm PDT/ 3:30pm ... President, Chief Executive Officer and Chairman of the ...
Cached Medicine Technology:Cynosure Receives International Marketing Clearances for New Cellulite, Laser Lipolysis Products 2Cynosure Receives International Marketing Clearances for New Cellulite, Laser Lipolysis Products 3
(Date:6/30/2015)... ... June 30, 2015 , ... Lakeview ... more than doubled the size of its medical staff to further enhance its ... which includes physicians, nurse practitioners and physician assistants -- now totals 17, compared ...
(Date:6/30/2015)... Plains, NJ (PRWEB) , ... June 30, 2015 , ... ... Techniques, they will be wowed with the incredible care that they receive and the ... care for their patients; but now they are proud to offer the same experience, ...
(Date:6/30/2015)... ... ... The U.S. Women's National Soccer Team will face the Costa Rica Women's National team ... August 16th at Heinz Field in Pittsburgh at 1:30 p.m. local time. On Wednesday, ... TN. , The USA WNT previously played at Heinz Field in Pittsburgh and won against ...
(Date:6/30/2015)... NY (PRWEB) , ... June 30, 2015 , ... ... newest oncology centers are partnering to improve access to cancer prevention, screening and ... Cancer Center (LCC) have announced an affiliation that will see Roswell Park faculty ...
(Date:6/30/2015)... ... June 30, 2015 , ... After more than five years ... Drug Administration, GlobalSun (TM) — sunscreen specifically formulated for the unique skin of all ... 35, hits the market just in time to help protect the skin of all ...
Breaking Medicine News(10 mins):Health News:Lakeview Health, a Nationally Recognized Drug Rehabilitation Center in Florida, Doubles Size of Medical Staff 2Health News:NJ Top Dentist, Dr. Laurence C. Breiterman is Now Offering the WOW Factor at His Highly Regarded Dental Practice 2Health News:NJ Top Dentist, Dr. Laurence C. Breiterman is Now Offering the WOW Factor at His Highly Regarded Dental Practice 3Health News:NJ Top Dentist, Dr. Laurence C. Breiterman is Now Offering the WOW Factor at His Highly Regarded Dental Practice 4Health News:USA vs. Costa Rica Tickets at Heinz Field in Pittsburgh and Finley Stadium in Chattanooga: Ticket Down Slashes Presale Ticket Prices for Costa Rica vs. USA WNT 2Health News:Intercontinental Oncology Partnership Brings Access to Specialized Cancer Care to Nigeria 2Health News:Intercontinental Oncology Partnership Brings Access to Specialized Cancer Care to Nigeria 3Health News:Intercontinental Oncology Partnership Brings Access to Specialized Cancer Care to Nigeria 4Health News:Intercontinental Oncology Partnership Brings Access to Specialized Cancer Care to Nigeria 5Health News:GlobalSun – The First Sunscreen Developed for All People of Color – Hits The Market 2
... Conference on Cell Therapy for Cardiovascular Disease sponsored ... comprehensive program dedicated to the evolving field of ... cardiac and vascular disease, as well as related ... conference will focus on preclinical and clinical studies ...
... The March of Dimes, along with its partners, are giving ... to learn from each other and to work together to ... give more babies a healthy start. U.S. Surgeon ... Prevention Symposium. The symposium will was a forum to share ...
... of researchers has discovered 13 new regions of the genome ... on the biological pathways involved in reproductive lifespan and will ... cancer and heart disease. Menopause is a ... in their early 50s. The timing of menopause can have ...
... Kathleen Doheny HealthDay Reporter , SUNDAY, Jan. ... genomic regions they believe are linked with breast cancer ... disease. All three newly identified areas "contain interesting ... clinical research," said researcher Douglas Easton, a professor of ...
... 2012) Research to Prevent Blindness (RPB) has awarded ... School, a $30,000 Medical Student Eye Research Fellowship. The award ... award will allow Ms. Shah to participate in research under ... Dr. Louis Pasquale in collaboration with Dr. Suzanne Freitag, Director ...
... By Steven Reinberg HealthDay Reporter , FRIDAY, Jan. ... moratorium on controversial research into a modified avian flu virus ... Although the investigators believe their research has a public ... others that the genetically altered virus could escape from labs ...
Cached Medicine News:Health News:Global conference on stem cell therapy for heart disease to be held Jan. 25-27 in NYC 2Health News:Global conference on stem cell therapy for heart disease to be held Jan. 25-27 in NYC 3Health News:March of Dimes launches Prematurity Prevention Network 2Health News:March of Dimes launches Prematurity Prevention Network 3Health News:Genes and timing of menopause 2Health News:New Genetic Clues to Breast Cancer? 2Health News:New Genetic Clues to Breast Cancer? 3Health News:Scientists Agree to Delay Controversial Bird Flu Research 2Health News:Scientists Agree to Delay Controversial Bird Flu Research 3
... If you prefer a standard ... the Volk Iridectomy Lens. Its ... view you're used to but ... Volk's exclusive Double Aspheric design ...
... 2.2 offers extremely high resolution treatment capability ... an exceptionally wide 78° field of view. ... critical evaluation of the optic nerve head ... of the macula and disc. Redesigned to ...
... for focal laser therapy and mid-to-far peripheral ... a realistic contour of the retinal concavity, ... entire posterior pole extending to the equator. ... dynamic movement on the globe, therefore increasing ...
... The Digital 1.0x Imaging Lens is optimized ... reduce glare and reflections during general diagnosis and ... view of the posterior pole and a sharper ... Digital 1.0 X Imaging Lens is also ideal ...
Medicine Products: